Drugs / Dendritic Cell Survivin Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT02851056 | Sep 2016 → Jul 2018 | plasma cell myeloma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dendritic Cell Survivin Vaccine | “The name of the vaccine is called Dendritic Cell Survivin Vaccine (DC:AdmS).” NCT02851056 ↗ |
| Known as | DC:AdmS | “The name of the vaccine is called Dendritic Cell Survivin Vaccine (DC:AdmS).” NCT02851056 ↗ |
| Modality | Vaccine | “The purpose of this study is to test what effects (good and bad) a new cancer vaccine will have on participants and their cancer, when administered before and after their...” NCT02851056 ↗ |